Q3: Commercial focus and efficiency measures beginning to deliver results

Q3 net sales rose 2.7% to SEK 5,225m (from SEK 5,089m), but organic sales growth was still up only 2.6% versus -2.9% a year ago, with SMB remaining weak at -11.9% (adjusted for consumer discontinuation: -5.3%). Gross margin improved to 14.4% (from 13.4%), and adjusted EBITA increased to SEK 118m (from SEK 72m; margin 2.3% vs 1.4%). However, EBIT swung to a loss of SEK -769m (from SEK 11m) due to a primarily goodwill non-cash impairment, signaling significant underlying headwinds despite revenue growth.

Analysis

The operating print reads better than the headline: gross margin improvement and a modest top-line rebound suggest the core franchise is stabilizing, but the quality of that improvement matters. A meaningful slice of the margin lift likely comes from exiting a lower-return consumer activity, which boosts reported profitability while shrinking the addressable base; that usually buys time, not a rerating, unless the remaining mix can keep compounding.

The real winner is the higher-growth operating segment, while the loser is the SMB book if it cannot get back to low-single-digit organic growth after the consumer exit is fully digested. That split matters because analysts will increasingly value the company as a narrower, more cyclical industrial platform rather than a diversified compounder, which typically compresses multiples even when margins improve. The goodwill impairment is non-cash, but it is an equity-story warning flag: it signals prior capital allocation overpaid for growth, and that tends to keep the market skeptical of future M&A until cash conversion and ROIC prove out.

Near term, the stock can bounce on the margin beat, but the cleaner catalyst path over 1-3 months is guidance on whether SMB stabilizes and whether working capital/capex normalize. Over 6-18 months, the thesis hinges on whether the remaining business can deliver sustained organic growth above inflation; if not, the market will treat this as a restructuring story, not a quality compounder. What would falsify the bearish view is a second consecutive quarter of mid-single-digit organic growth in the core segment plus no further write-downs.

Key Decisions for Investors

• No high-conviction trade on the print alone; wait 1-2 sessions for the market to separate margin quality from mix effects before acting.
• If you hold the name, trim on any post-earnings strength unless management can point to 2H organic stabilization in SMB and cash conversion improvement; otherwise the rerating risk is limited.
• Use a relative-value lens: favor the stronger operating segment exposure versus any European small-cap industrial/distribution peer still carrying consumer or low-return SMB drag; the spread should widen if analysts cut forward estimates.
• Set an alert for the next guidance update and balance-sheet commentary; if another non-cash write-down or downward organic guide appears, the equity should be treated as a value trap rather than a recovery story.